- Home
- TC vs BJDX Comparison
TC vs BJDX Comparison
Compare TC & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TC
- BJDX
- Stock Information
- Founded
- TC 2010
- BJDX 2015
- Country
- TC China
- BJDX United States
- Employees
- TC N/A
- BJDX N/A
- Industry
- TC Business Services
- BJDX Medical Specialities
- Sector
- TC Consumer Discretionary
- BJDX Health Care
- Exchange
- TC Nasdaq
- BJDX Nasdaq
- Market Cap
- TC 1.7M
- BJDX 1.8M
- IPO Year
- TC 2018
- BJDX 2021
- Fundamental
- Price
- TC $0.92
- BJDX $4.05
- Analyst Decision
- TC
- BJDX
- Analyst Count
- TC 0
- BJDX 0
- Target Price
- TC N/A
- BJDX N/A
- AVG Volume (30 Days)
- TC 192.7K
- BJDX 959.8K
- Earning Date
- TC 12-27-2024
- BJDX 11-07-2024
- Dividend Yield
- TC N/A
- BJDX N/A
- EPS Growth
- TC N/A
- BJDX N/A
- EPS
- TC N/A
- BJDX N/A
- Revenue
- TC $14,107,804.00
- BJDX N/A
- Revenue This Year
- TC N/A
- BJDX N/A
- Revenue Next Year
- TC N/A
- BJDX N/A
- P/E Ratio
- TC N/A
- BJDX N/A
- Revenue Growth
- TC N/A
- BJDX N/A
- 52 Week Low
- TC $0.75
- BJDX $3.03
- 52 Week High
- TC $4.30
- BJDX $1,272.00
- Technical
- Relative Strength Index (RSI)
- TC 47.11
- BJDX 48.88
- Support Level
- TC $0.82
- BJDX $4.30
- Resistance Level
- TC $1.00
- BJDX $5.49
- Average True Range (ATR)
- TC 0.09
- BJDX 0.67
- MACD
- TC 0.01
- BJDX 0.11
- Stochastic Oscillator
- TC 40.35
- BJDX 25.52
About TC TuanChe Limited
TuanChe Ltd is an omnichannel automotive marketplace in China. The company operates in one operating segment of providing auto shows, special promotion events services, and virtual dealership, online marketing services, and others. It organizes auto shows, which aim at facilitating transactions between consumers and auto dealers that include auto dealers, automakers, and automotive service providers. It provides services through its online platform and offline events.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.